Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

DZ Bank upgraded Sanofi (SNY) to Buy from Hold with a EUR 122 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See ...

We exceeded our business EPS guidance. In 2024, we announced an intention to sell a controlling stake in Opella consumer health, which will make Sanofi (SNY) a focused, science-driven biopharma ...

-Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

In other deals, Linklaters, Willkie and Latham are advising as PAI Partners negotiates to buy a stake in Alvest, a France-based provider of ground support equipment for airports, in a deal worth an ...